Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Paul Turnbull

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Silos – a reflection on the second birthday of Porterhouse Insights

After another exciting year, Fabrice Allum, Managing Director at Porterhouse Insights, reflects on the benefits of cross-functional working for our pharmaceutical clients

Porterhouse Medical Group

- PMLiVE

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

Drug is on course for blockbuster sales

- PMLiVE

UK’s CMA clears Roche’s $4.3bn takeover of Spark

Roche first announced deal in February

- PMLiVE

Roche’s Tecentriq combo scores in first-line melanoma

Plans to file treatment with health authorities on strength of data

- PMLiVE

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent

- PMLiVE

Novartis ditches oral asthma drug after disappointing phase 3 readout

Bad news for Gossamer’s would-be rival DP2 antagonist

- PMLiVE

UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner

Final Senate vote was 72 to 18 in favour of the radiation oncology expert

- PMLiVE

GCI Health opens new office in Hong Kong

Will be led by newly appointed director Yvonne Yeung

- PMLiVE

Horizon looks bright as FDA panel backs eye drug teprotumumab

First alternative to surgery for proptosis

- PMLiVE

Novel endpoints in the digital age

Redesigning the goalposts

- PMLiVE

Brexit nears as Conservatives sweep to victory in election

British pharma association 'looks forward to working with the new Government'

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links